B7688
PiB
≥98% (HPLC)
Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C22H18N2O8
CAS Number:
Molecular Weight:
438.39
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Product Name
PiB, ≥98% (HPLC)
InChI key
WNKQGFNIIHNGQM-UHFFFAOYSA-N
SMILES string
O=C(C1=C2C(C3=CC=C24)=C(C(N(CC(OCC)=O)C3=O)=O)C=C1)N(CC(OCC)=O)C4=O
InChI
1S/C22H18N2O8/c1-3-31-15(25)9-23-19(27)11-5-7-13-18-14(8-6-12(17(11)18)20(23)28)22(30)24(21(13)29)10-16(26)32-4-2/h5-8H,3-4,9-10H2,1-2H3
assay
≥98% (HPLC)
form
powder
color
white to light brown
solubility
DMSO: 1-2 mg/mL (warmed)
storage temp.
2-8°C
Quality Level
Related Categories
Biochem/physiol Actions
PiB is a Pin-1 inhibitor.
PiB is an inhibitor of the peptidylprolyl isomerase Pin-1. Inhibition of Pin-1 leads to destabilization of the transcription factor Nanog, which is required for maintenance of embryonic stem cell cultures.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Sven H C Askes et al.
Small (Weinheim an der Bergstrasse, Germany), 12(40), 5579-5590 (2016-10-21)
Light upconversion is a very powerful tool in bioimaging as it can eliminate autofluorescence, increase imaging contrast, reduce irradiation damage, and increase excitation penetration depth in vivo. In particular, triplet-triplet annihilation upconverting (TTA-UC) nanoparticles and liposomes offer high upconversion efficiency
Lisa Vermunt et al.
Neurology, 92(23), e2699-e2705 (2019-05-10)
To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative.
Takamasa Yokoi et al.
Frontiers in aging neuroscience, 10, 304-304 (2018-10-23)
Background: Imaging studies in Alzheimer's disease (AD) have yet to answer the underlying questions concerning the relationship among tau retention, neuroinflammation, network disruption and cognitive decline. We compared the spatial retention patterns of 18F-THK5351 and resting state network (RSN) disruption
Christopher M Lee et al.
Journal of Alzheimer's disease : JAD, 62(4), 1691-1702 (2018-04-05)
On target 18F-Flortaucipir (FTP) binding of Alzheimer's disease tau aggregates and off-target binding of melanocytes have been demonstrated with autoradiography. We aimed to investigate the hypothesis that if binding in choroid plexus (CP) is due to melanocytes, the signal would
Inge M W Verberk et al.
Alzheimer's research & therapy, 12(1), 118-118 (2020-09-30)
Blood-based biomarkers for Alzheimer's disease (AD) might facilitate identification of participants for clinical trials targeting amyloid beta (Abeta) accumulation, and aid in AD diagnostics. We examined the potential of plasma markers Abeta(1-42/1-40), glial fibrillary acidic protein (GFAP) and neurofilament light
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service